![](/wp-content/uploads/2023/08/Screenshot-2023-08-10-at-11.28.13-AM.png)
$599
Novo Nordisk Q2 ’23 Earnings Update
Novo Nordisk hosted its Q2 ’23 earnings call (view press release; slides) and provided updates across its CVRM portfolio, including the recently announced SELECT CVOT topline results, Wegovy supply, and the high-dose oral semaglutide regulatory submission. Importantly, senior management disclosed plans to present full SELECT CVOT results at AHA 2023 in Philadelphia (November 11-13). Below, FENIX provides highlights and insights from the earnings call.